Brind.
  1. Arrowhead Pharmaceuticals and Sarepta entered into a collaboration regarding siRNA programs, including licensing agreement payments starting on August 19, 2025.

Arrowhead and Sarepta reached clinical and licensing milestones in their collaboration regarding siRNA programs.

1 report, 1 independent Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Arrowhead and Sarepta reached clinical and licensing milestones in their collaboration regarding siRNA programs.

Who's involved

What this event is mainly about
Arrowhead PharmaceuticalsSarepta Therapeutics

Keep exploring

Part of

Arrowhead Pharmaceuticals and Sarepta entered into a collaboration regarding siRNA programs, including licensing agreement payments starting on August 19, 2025. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireArrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Milestone earned upon reaching first enrollment target in a Phase 1/2 study of ARO-DM1 for the treatment of type 1 m